Zevra Therapeutics, Inc.
ZVRA
$11.05
$0.252.32%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 122.29M | 106.47M | 84.39M | 62.02M | 40.59M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 122.29M | 106.47M | 84.39M | 62.02M | 40.59M |
| Cost of Revenue | 17.03M | 16.48M | 16.33M | 17.39M | 8.59M |
| Gross Profit | 105.26M | 89.99M | 68.06M | 44.63M | 32.00M |
| SG&A Expenses | 78.95M | 77.71M | 73.44M | 72.71M | 64.53M |
| Depreciation & Amortization | 2.56M | 3.86M | 5.16M | 6.39M | 6.32M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 112.33M | 110.70M | 113.35M | 122.43M | 112.47M |
| Operating Income | 9.96M | -4.23M | -28.96M | -60.41M | -71.88M |
| Income Before Tax | 133.40M | 86.68M | 53.64M | 21.40M | -75.37M |
| Income Tax Expenses | 9.18M | 3.45M | 18.32M | 18.75M | 16.62M |
| Earnings from Continuing Operations | 124.22 | 83.23 | 35.33 | 2.64 | -91.99 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 124.22M | 83.23M | 35.33M | 2.64M | -91.99M |
| EBIT | 9.96M | -4.23M | -28.96M | -60.41M | -71.88M |
| EBITDA | 12.73M | -179.00K | -23.62M | -53.85M | -65.40M |
| EPS Basic | 2.09 | 1.41 | 0.53 | -0.15 | -1.90 |
| Normalized Basic EPS | 0.11 | -0.04 | -0.42 | -0.84 | -0.99 |
| EPS Diluted | 2.02 | 1.36 | 0.50 | -0.19 | -1.90 |
| Normalized Diluted EPS | 0.10 | -0.04 | -0.41 | -0.84 | -0.99 |
| Average Basic Shares Outstanding | 225.54M | 221.22M | 218.30M | 210.16M | 197.28M |
| Average Diluted Shares Outstanding | 231.21M | 225.07M | 219.85M | 211.70M | 197.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |